meREWARDS allows you to get coupons and earn cash when you answer surveys, dinners and purchases with our partners
BANDUNG: Indonesia will take priority over technical knowledge on the production of the Chinese-made COVID-19 vaccine once the candidate has received regulatory approval, an official said wednesday (August 12).
This is a component of Indonesia’s involvement in the complex human trial of the candidate vaccine produced through Sinovac Biotech, which is one of the few in the world involved in Phase 3 clinical trials.
“Of course we will have priority, it is their commitment,” said Rini Mulia Sari, Head of Bio Farma’s Test.
Bio Farma, a state-owned pharmaceutical company and vaccine producer in the country, has partnered with the University of Padjajaran to conduct trials in Indonesia.
They will be the candidate vaccine, known as CoronaVac, over 1,620 volunteers over six months. Sinovac will also conduct trials in several other countries such as Brazil and Bangladesh.
“There will also be a generation transfer. Then the ones that will be announced (in Indonesia) will be the ones that are made in Bio Farma, which means that it will bring the Brand Bio Farma,” Sari said at a press conference at Bio Farma’s facility. in Bandung.
The generational movement would come with the formula for producing the vaccine, a corporate spokesman said.
Officials of the corporate pharmaceutical idea that the vaccine could be in a position to be used in March of next year.
In addition to this partnership with Sinovac, Indonesia is developing its own vaccine.
It also works with other vaccine-producing countries such as South Korea and the United Arab Emirates.
The Sinovac clinical trial in Indonesia came at a time when Southeast Asia’s largest economy was suffering from involving the spread of COVID-19. More than 130,000 infections were recorded on Wednesday, with around 5,900 deaths.
Download our app or subscribe to our Telegram channel to receive updates on the coronavirus outbreak: https://cna.asia/telegram